Nuo Therapeutics, Inc.
corporate_fare Company Profile
Nuo Therapeutics, Inc. (OTC:AURX) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 11 items for AURX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for AURX spans 8-K, 10-Q, SCHEDULE 13D/A.
Recent high-impact activity:
- Nuo Posts 80% Q3 Revenue Growth, Wins 7% Medicare Reimbursement Increase for 2027
- Nuo Q3 Revenue Jumps 81% to $1.87M, But Going Concern Doubt Persists on $81K Cash
- Nuo Therapeutics Q2 Revenue Jumps 150% to $1.77M, Loss Narrows to $167K
- Nuo Therapeutics Q2 Revenue Jumps 150% as Losses Narrow; Loan Amended
- Supply Chain Disruption and Going Concern Doubt Flagged by Nuo Therapeutics
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 4,326 shares in AURX as of the October 30, 2026 settlement, a 4872.4% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 99.1% of AURX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.